Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by PSBon Aug 29, 2021 2:04pm
258 Views
Post# 33779636

MCNA Bladder cancer treatment......

MCNA Bladder cancer treatment......
I never hear anyone on this board discuss the potential residual value the MCNA Bladder cancer technology for Humans may have after it was "put on the shelf" by Prometic Life Sciences (now LMNL) back in 2016. MCNA was "shelved" because the FDA required an additional Phase 3 (B) trial with a larger number of participants and that would add another 3 to 4 years of money and study before granting approval. Bioniche/Telesta's spent 100's of millions of dollars on this technology attaining a Phase 3 (A) review by the FDA advisary committee back in 2015. The FDA review comittee did not recommend by a 18 (no) and 6 (yes) vote with most Urologist on the panel voting yes.

https://www.biospace.com/article/releases/fda-panel-rejects-telesta-s-bladder-cancer-drug-mcna-/

Interesting how this technology just sits on the shelf hidden away somewhere and never discussed or brought up after Prometic Life Sciences morphed into LMNL. I've never heard a word about it for years. It's also interesting how this technology is working with former CEO of Bioniche, Graeme McRae's new company NovaVive in animal cancers.

https://www.novavive.ca/assets/files/NovaVive%20Corporate%20Overview-08.21.pdf
<< Previous
Bullboard Posts
Next >>